[8-K] Chemours Co Reports Material Event
The Chemours Company amended its credit agreement, extending the maturity of its $1,050,000,000 senior secured U.S. dollar term loan (Term Loan B-3) from August 18, 2028 to October 15, 2032. The loan’s pricing was reset to either adjusted Term SOFR + 3.50% or adjusted base rate + 2.50%, at the company’s election.
Separately, several wholly owned European subsidiaries entered a receivables purchase agreement with BNP Paribas Factor allowing sales of eligible receivables up to an aggregate outstanding balance of €180,000,000. The initial term runs through October 14, 2026 with automatic one-year extensions, and Chemours acceded to joint and several liability for seller obligations. Receivables are sold at their nominal amount less customary deductions, with applicable interest and fees payable to BNP.
La Chemours Company ha modificato il suo accordo di credito, estendendo la scadenza del suo prestito a termine senior secured denominato in dollari USA di $1,050,000,000 (Term Loan B-3) dall'18 agosto 2028 al 15 ottobre 2032. Il prezzo del prestito è stato nuovamente fissato a SOFR rettificato + 3,50% o a tasso base rettificato + 2,50%, a scelta della società.
Separatamente, diverse controllate europee interamente di proprietà hanno stipulato un accordo di acquisto di crediti con BNP Paribas Factor che consente la vendita di crediti idonei fino a un saldo complessivo in essere di €180.000.000. Il termine iniziale scade il 14 ottobre 2026 con estensioni automatiche di un anno, e Chemours ha aderito alla responsabilità solidale per gli obblighi del venditore. I crediti vengono venduti al loro importo nominale meno le detrazioni consuete, con interessi e oneri applicabili pagabili a BNP.
La Compañía Chemours enmendó su acuerdo de crédito, extendiendo el vencimiento de su préstamo a plazo senior garantizado en dólares estadounidenses de $1,050,000,000 (Term Loan B-3) desde el 18 de agosto de 2028 hasta el 15 de octubre de 2032. El precio del préstamo se restableció a SOFR ajustado + 3,50% o a la tasa base ajustada + 2,50%, a elección de la empresa.
Separadamente, varias filiales europeas enteramente propietarias firmaron un acuerdo de compra de cuentas por cobrar con BNP Paribas Factor que permite la venta de cuentas por cobrar elegibles hasta un saldo pendiente agregado de €180,000,000. El plazo inicial vence el 14 de octubre de 2026 con prorrogas automáticas de un año, y Chemours accedió a la responsabilidad solidaria por las obligaciones del vendedor. Las cuentas por cobrar se venden por su monto nominal menos deducciones habituales, con intereses y comisiones aplicables pagaderos a BNP.
The Chemours Company는 신용 계약을 수정하여 미국 달러로 표시된 우선 담보 대출(Term Loan B-3)의 만기를 2028년 8월 18일에서 2032년 10월 15일로 연장했습니다. 대출의 금리 구조는 회사의 선택에 따라 조정된 Term SOFR + 3.50% 또는 조정된 기준 금리 + 2.50%로 재설정되었습니다.
또한, 여러 전액 출자 유럽 자회사들이 BNP Paribas Factor와 매출 채권 매입 계약을 체결하여 총 미결제 잔액이 €180,000,000에 달하는 적격 채권의 매각이 가능해졌습니다. 초기 기간은 2026년 10월 14일까지이며 자동 1년 연장이 가능하고, Chemours는 매도자의 채무에 대해 연대 책임에 동의했습니다. 매각된 채권은 일반적인 공제액을 차감한 명목 금액으로 매각되며, BNP에 대해 적용 이자와 수수료가 지급됩니다.
La société The Chemours Company a modifié son accord de crédit, prolongeant l’échéance de son prêt à terme senior garanti libellé en dollars américains de 1 050 000 000 $ (Term Loan B-3) du 18 août 2028 au 15 octobre 2032. Le taux du prêt a été réinitialisé soit sur SOFR ajusté + 3,50%, soit sur le taux de référence ajusté + 2,50%, au choix de l’entreprise.
Par ailleurs, plusieurs filiales européennes entièrement détenues ont conclu un accord d’achat de créances avec BNP Paribas Factor, permettant la vente de créances éligibles jusqu’à un solde dû total de €180 000 000. La durée initiale se termine le 14 octobre 2026 avec des prolongations automatiques d’un an, et Chemours a accepté la responsabilité solidaire pour les obligations du vendeur. Les créances sont vendues à leur montant nominal moins les déductions usuelles, avec les intérêts et frais applicables payables à BNP.
The Chemours Company hat seine Kreditvereinbarung geändert und die Fälligkeit des vorrangig besicherten Dollar-Teilskredits (Term Loan B-3) von 1.050.000.000 $ auf 15. Oktober 2032 verlängert, nach dem ursprünglichen Datum 18. August 2028. Die Zinssatzstruktur des Darlehens wurde auf entweder angepasstes Term SOFR + 3,50% oder angepasstes Basiszinssatz + 2,50% neu festgelegt, nach Wahl des Unternehmens.
Separat haben mehrere vollständig im Besitz befindliche europäische Tochtergesellschaften eine Forderungskaufvereinbarung mit BNP Paribas Factor abgeschlossen, die den Verkauf von zulässigen Forderungen bis zu einem Gesamtstand von €180.000.000 ermöglicht. Die Erstlaufzeit läuft bis zum 14. Oktober 2026 mit automatischen Verlängerungen um jeweils ein Jahr, und Chemours hat sich der solidarischen Haftung für Verkäuferverpflichtungen angeschlossen. Forderungen werden zu ihrem Nominalwert abzüglich üblicher Abzüge verkauft, mit anfallenden Zinsen und Gebühren zugunsten von BNP.
شركة Chemours عدّلت اتفاقية الائتمان لديها، ممددة الأجل لسندها القائم على الدولار الأمريكي من فئة القرض القائم على الدين $1,050,000,000 (Term Loan B-3) من 18 أغسطس 2028 إلى 15 أكتوبر 2032. تم إعادة تعيين تسعير القرض ليكون إما SOFR معدل قابل للتعديل + 3.50% أو معدل الأساس القابل للتعديل + 2.50%، وفق اختيار الشركة.
على نحو منفصل، دخلت عدة فروع أوروبية مملوكة بالكامل في اتفاقية شراء ذمم مدينة مع BNP Paribas Factor تمكن من بيع الذمم المستحقة المؤهلة حتى رصيد مستحق إجمالي قدره €180,000,000. مدة السلسلة الأولية تمتد حتى 14 أكتوبر 2026 مع تمديدات تلقائية لسنة واحدة، ووافقت Chemours على تحمل المسؤولية المشتركة والتضامنية عن التزامات البائع. يتم بيع الذمم المدينة بمبلغها الاسمي ناقص الاستقطاعات المعتادة، وتُدفع فائدة ورسوم قابلة للدفتر إلى BNP.
The Chemours Company 修改了其信贷协议，将以美元计价的高级担保定期贷款（Term Loan B-3）的到期日从 2028年8月18日延长至 2032年10月15日，金额为 $1,050,000,000。贷款利率被重设为经调整的 Term SOFR + 3.50% 或经调整的基准利率 + 2.50%，以公司选择为准。
此外，几家全资位于欧洲的子公司与 BNP Paribas Factor 签署了应收账款购买协议，允许出售符合条件的应收账款，未清余额总额不超过 €180,000,000。初始期限至 2026年10月14日，并可自动延长一年，Chemours 同意对卖方义务承担连带责任。应收账款按票面金额净额出售，扣除通常扣除项，向 BNP 支付相应的利息和费用。
- None.
- None.
Insights
Maturity pushed to 2032 and €180M factoring add liquidity options.
Chemours extended its Term Loan B-3 maturity to
The receivables purchase agreement with BNP permits up to
Key dependencies include usage levels under the factoring cap and adherence to covenants and eligibility criteria in the agreements. Subsequent disclosures may quantify utilization and any impact on working capital metrics.
La Chemours Company ha modificato il suo accordo di credito, estendendo la scadenza del suo prestito a termine senior secured denominato in dollari USA di $1,050,000,000 (Term Loan B-3) dall'18 agosto 2028 al 15 ottobre 2032. Il prezzo del prestito è stato nuovamente fissato a SOFR rettificato + 3,50% o a tasso base rettificato + 2,50%, a scelta della società.
Separatamente, diverse controllate europee interamente di proprietà hanno stipulato un accordo di acquisto di crediti con BNP Paribas Factor che consente la vendita di crediti idonei fino a un saldo complessivo in essere di €180.000.000. Il termine iniziale scade il 14 ottobre 2026 con estensioni automatiche di un anno, e Chemours ha aderito alla responsabilità solidale per gli obblighi del venditore. I crediti vengono venduti al loro importo nominale meno le detrazioni consuete, con interessi e oneri applicabili pagabili a BNP.
La Compañía Chemours enmendó su acuerdo de crédito, extendiendo el vencimiento de su préstamo a plazo senior garantizado en dólares estadounidenses de $1,050,000,000 (Term Loan B-3) desde el 18 de agosto de 2028 hasta el 15 de octubre de 2032. El precio del préstamo se restableció a SOFR ajustado + 3,50% o a la tasa base ajustada + 2,50%, a elección de la empresa.
Separadamente, varias filiales europeas enteramente propietarias firmaron un acuerdo de compra de cuentas por cobrar con BNP Paribas Factor que permite la venta de cuentas por cobrar elegibles hasta un saldo pendiente agregado de €180,000,000. El plazo inicial vence el 14 de octubre de 2026 con prorrogas automáticas de un año, y Chemours accedió a la responsabilidad solidaria por las obligaciones del vendedor. Las cuentas por cobrar se venden por su monto nominal menos deducciones habituales, con intereses y comisiones aplicables pagaderos a BNP.
The Chemours Company는 신용 계약을 수정하여 미국 달러로 표시된 우선 담보 대출(Term Loan B-3)의 만기를 2028년 8월 18일에서 2032년 10월 15일로 연장했습니다. 대출의 금리 구조는 회사의 선택에 따라 조정된 Term SOFR + 3.50% 또는 조정된 기준 금리 + 2.50%로 재설정되었습니다.
또한, 여러 전액 출자 유럽 자회사들이 BNP Paribas Factor와 매출 채권 매입 계약을 체결하여 총 미결제 잔액이 €180,000,000에 달하는 적격 채권의 매각이 가능해졌습니다. 초기 기간은 2026년 10월 14일까지이며 자동 1년 연장이 가능하고, Chemours는 매도자의 채무에 대해 연대 책임에 동의했습니다. 매각된 채권은 일반적인 공제액을 차감한 명목 금액으로 매각되며, BNP에 대해 적용 이자와 수수료가 지급됩니다.
La société The Chemours Company a modifié son accord de crédit, prolongeant l’échéance de son prêt à terme senior garanti libellé en dollars américains de 1 050 000 000 $ (Term Loan B-3) du 18 août 2028 au 15 octobre 2032. Le taux du prêt a été réinitialisé soit sur SOFR ajusté + 3,50%, soit sur le taux de référence ajusté + 2,50%, au choix de l’entreprise.
Par ailleurs, plusieurs filiales européennes entièrement détenues ont conclu un accord d’achat de créances avec BNP Paribas Factor, permettant la vente de créances éligibles jusqu’à un solde dû total de €180 000 000. La durée initiale se termine le 14 octobre 2026 avec des prolongations automatiques d’un an, et Chemours a accepté la responsabilité solidaire pour les obligations du vendeur. Les créances sont vendues à leur montant nominal moins les déductions usuelles, avec les intérêts et frais applicables payables à BNP.
The Chemours Company hat seine Kreditvereinbarung geändert und die Fälligkeit des vorrangig besicherten Dollar-Teilskredits (Term Loan B-3) von 1.050.000.000 $ auf 15. Oktober 2032 verlängert, nach dem ursprünglichen Datum 18. August 2028. Die Zinssatzstruktur des Darlehens wurde auf entweder angepasstes Term SOFR + 3,50% oder angepasstes Basiszinssatz + 2,50% neu festgelegt, nach Wahl des Unternehmens.
Separat haben mehrere vollständig im Besitz befindliche europäische Tochtergesellschaften eine Forderungskaufvereinbarung mit BNP Paribas Factor abgeschlossen, die den Verkauf von zulässigen Forderungen bis zu einem Gesamtstand von €180.000.000 ermöglicht. Die Erstlaufzeit läuft bis zum 14. Oktober 2026 mit automatischen Verlängerungen um jeweils ein Jahr, und Chemours hat sich der solidarischen Haftung für Verkäuferverpflichtungen angeschlossen. Forderungen werden zu ihrem Nominalwert abzüglich üblicher Abzüge verkauft, mit anfallenden Zinsen und Gebühren zugunsten von BNP.
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported)
(Exact Name of Registrant as Specified in Its Charter)
|
|
|||
(State or Other Jurisdiction |
|
(Commission |
|
(I.R.S. Employer |
Of Incorporation) |
|
File Number) |
|
Identification No.) |
(Address of principal executive offices)
Registrant’s telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class |
|
Trading Symbol(s) |
|
Name of Exchange on Which Registered |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company |
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. |
|
☐ |
|
Item 1.01 Entry into a Material Definitive Agreement.
On October 15, 2025 (the “Amendment No. 4 Effective Date”), The Chemours Company (the “Company”) entered into Amendment No. 4 (the “Amendment”) by and among the Company, The Chemours Company FC, LLC, the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the “Administrative Agent”), which amends the Second Amended and Restated Credit Agreement, dated as of August 18, 2023, among the Company, the lenders from time to time party thereto and the Administrative Agent (as amended, supplemented or otherwise modified from time to time prior to October 15, 2025, the “Existing Credit Agreement” and as amended by the Amendment, the “Credit Agreement”). The Amendment extended the maturity date of the Company’s $1,050,000,000 senior secured U.S. dollar-denominated term loan facility (the “Term Loan B-3 US$ Facility”) from August 18, 2028 to October 15, 2032. The Amendment changed the applicable margin in respect of the Term Loan B-3 US$ Facility to, at the election of the Company, adjusted Term SOFR + 3.50% or adjusted base rate plus 2.50%.
The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under Off-Balance Sheet Arrangement of a Registrant.
The information set forth in Item 1.01 is incorporated herein by reference.
Item 8.01 Other Events.
On October 13, 2025 (the “Factor Closing Date”), Chemours Deutschland GmbH, a private company with limited liability incorporated under the laws of Germany, Chemours International Operations Sarl, a private company with limited liability incorporated under the laws of Switzerland, Chemours Netherlands BV, a private company with limited liability incorporated under the laws of Netherlands, Chemours International BV, a private company with limited liability incorporated under the laws of Netherlands, Chemours UK Limited, a private company with limited liability incorporated under the laws of the United Kingdom, and Chemours Belgium BV, a private company with limited liability incorporated under the laws of Belgium (collectively, the “Chemours Sellers”), entered into a Receivables Purchase Agreement (the “Purchase Agreement”) with BNP Paribas Factor GmbH (“BNP”). On October 14, 2025, the Company, acceded to joint and several liability for all liabilities of the Chemours Sellers under the Receivables Purchase Agreement. Each of the Chemours Sellers is a direct or indirect wholly-owned subsidiary of the Company.
Pursuant to the Purchase Agreement, and subject to the terms and conditions set forth therein, the Chemours Sellers agree to offer for sale and to sell, and BNP agrees to purchase, certain eligible receivables and related rights in an amount of up to an aggregate outstanding balance of €180,000,000. The Purchase Agreement contains customary representations, warranties and covenants.
The initial term of the Purchase Agreement extends through October 14, 2026 and will be automatically extended for one-year period, unless earlier terminated in accordance with the terms of the Purchase Agreement. Pursuant to the Purchase Agreement, the purchase price for receivables sold pursuant to the Purchase Agreement will be the nominal amount of such receivables, less customary deductions. The Chemours Sellers and the Company will be obligated to pay applicable interest and fees to BNP.
The foregoing description is only a summary of the Receivables Purchase Agreement, and is qualified in its entirety by reference to the full text of the Receivables Purchase Agreement, which is filed as Exhibit 99.1 hereto, and which is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
10.1 |
Amendment No. 4, dated as of October 15, 2025, by and among The Chemours Company, The Chemours Company FC, LLC, the Lenders party thereto and JPMorgan Chase Bank, N.A., as Administrative Agent, to the Second Amended and Restated Credit Agreement dated as of August 18, 2023. |
99.1* |
Receivables Purchase Agreement, dated as of October 13, 2025, by and between Chemours Deutschland GmbH, Chemours International Operations Sarl, Chemours Netherlands BV, Chemours International BV, Chemours UK Limited and Chemours Belgium BV and BNP Paribas Factor GmbH. |
104 |
Cover Page Interactive Data File (formatted as Inline XBRL). |
* Annexes, schedules and/or exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted attachment to the SEC on a confidential basis upon request.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
THE CHEMOURS COMPANY |
||
|
||
By: |
|
/s/ Shane Hostetter |
|
|
Shane Hostetter |
|
|
Senior Vice President, Chief Financial Officer |
Date: |
|
October 15, 2025 |
FAQ
What did Chemours (CC) change in its term loan?
What is the size of Chemours’ new receivables program with BNP?
How long does the BNP receivables agreement run for CC?
What price will BNP pay for receivables from Chemours’ subsidiaries?
Did Chemours guarantee the receivables program obligations?
Which subsidiaries are party to the receivables agreement?
